Anixa Biosciences Net Worth
Anixa Biosciences Net Worth Breakdown | ANIX |
Anixa Biosciences Net Worth Analysis
Anixa Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Anixa Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Anixa Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Anixa Biosciences' net worth analysis. One common approach is to calculate Anixa Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Anixa Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Anixa Biosciences' net worth. This approach calculates the present value of Anixa Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Anixa Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Anixa Biosciences' net worth. This involves comparing Anixa Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Anixa Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Anixa Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Anixa Biosciences' net worth research are outlined below:
| Anixa Biosciences generated a negative expected return over the last 90 days | |
| Anixa Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (12.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Anixa Biosciences currently holds about 31.66 M in cash with (7.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| Anixa Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: Acquisition by Gottschalk Emily of 20065 shares of Anixa Biosciences at 3.96 subject to Rule 16b-3 |
Anixa Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Anixa Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anixa Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 12th of June 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 21st of January 2025 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 31st of October 2023 Last Financial Announcement | View |
Anixa Biosciences Target Price Consensus
Anixa target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Anixa Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Anixa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Anixa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Anixa Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAnixa Biosciences Target Price Projection
Anixa Biosciences' current and average target prices are 2.66 and 8.50, respectively. The current price of Anixa Biosciences is the price at which Anixa Biosciences is currently trading. On the other hand, Anixa Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Anixa Biosciences Market Quote on 12th of March 2025
Target Price
Analyst Consensus On Anixa Biosciences Target Price
Know Anixa Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anixa Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anixa Biosciences backward and forwards among themselves. Anixa Biosciences' institutional investor refers to the entity that pools money to purchase Anixa Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Citadel Advisors Llc | 2024-12-31 | 87.9 K | |
| The Colony Group Llc | 2024-12-31 | 70 K | |
| Northern Trust Corp | 2024-12-31 | 66.7 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 58.7 K | |
| Corecap Advisors, Llc | 2024-12-31 | 44.8 K | |
| Lpl Financial Corp | 2024-12-31 | 42.9 K | |
| Tyler-stone Wealth Management | 2024-12-31 | 42 K | |
| International Assets Investment Management, Llc | 2024-09-30 | 37.8 K | |
| Ci Private Wealth Llc | 2024-12-31 | 37.4 K | |
| Vanguard Group Inc | 2024-12-31 | 1.4 M | |
| Davidson D A & Co | 2024-12-31 | 671.1 K |
Follow Anixa Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.54 M.Market Cap |
|
Project Anixa Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (0.72) | (0.76) |
When accessing Anixa Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Anixa Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Anixa Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Anixa Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anixa Biosciences. Check Anixa Biosciences' Beneish M Score to see the likelihood of Anixa Biosciences' management manipulating its earnings.
Evaluate Anixa Biosciences' management efficiency
Anixa Biosciences has return on total asset (ROA) of (0.367) % which means that it has lost $0.367 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.601) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 250.2 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.68 | 0.65 | |
| Tangible Book Value Per Share | 0.68 | 0.65 | |
| Enterprise Value Over EBITDA | (7.20) | (7.56) | |
| Price Book Value Ratio | 6.42 | 6.10 | |
| Enterprise Value Multiple | (7.20) | (7.56) | |
| Price Fair Value | 6.42 | 6.10 | |
| Enterprise Value | 134.1 M | 134.2 M |
The operational strategies employed by Anixa Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anixa Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anixa Biosciences Corporate Filings
10Q | 11th of March 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 6th of February 2025 Other Reports | ViewVerify | |
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 10th of January 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Anixa Biosciences Earnings Estimation Breakdown
The calculation of Anixa Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Anixa Biosciences is estimated to be -0.1 with the future projection ranging from a low of -0.1 to a high of -0.1. Please be aware that this consensus of annual earnings estimates for Anixa Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.1 Lowest | Expected EPS | -0.1 Highest |
Anixa Biosciences Earnings Projection Consensus
Suppose the current estimates of Anixa Biosciences' value are higher than the current market price of the Anixa Biosciences stock. In this case, investors may conclude that Anixa Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Anixa Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of January 2025 | Current EPS (TTM) | |
| 2 | 89.56% | -0.09 | -0.1 | -0.39 |
Anixa Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Anixa Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Anixa Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Anixa Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Anixa Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Anixa Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Anixa Biosciences should always be considered in relation to other companies to make a more educated investment decision.Anixa Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Anixa Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-01-01 | 2024-10-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2024-09-06 | 2024-07-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2024-06-04 | 2024-04-30 | -0.11 | -0.1 | 0.01 | 9 | ||
2024-03-12 | 2024-01-31 | -0.09 | -0.1 | -0.01 | 11 | ||
2024-01-16 | 2023-10-31 | -0.09 | -0.09 | 0.0 | 0 | ||
2023-09-06 | 2023-07-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2023-06-14 | 2023-04-30 | -0.11 | -0.07 | 0.04 | 36 | ||
2023-03-17 | 2023-01-31 | -0.16 | -0.08 | 0.08 | 50 | ||
2023-01-04 | 2022-10-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2022-09-09 | 2022-07-31 | -0.13 | -0.09 | 0.04 | 30 | ||
2022-06-10 | 2022-04-30 | -0.13 | -0.12 | 0.01 | 7 | ||
2022-03-11 | 2022-01-31 | -0.13 | -0.13 | 0.0 | 0 | ||
2022-01-04 | 2021-10-31 | -0.09 | -0.13 | -0.04 | 44 | ||
2021-09-01 | 2021-07-31 | -0.08 | -0.14 | -0.06 | 75 | ||
2021-06-10 | 2021-04-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2021-03-11 | 2021-01-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2021-01-07 | 2020-10-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2020-09-08 | 2020-07-31 | -0.12 | -0.1 | 0.02 | 16 | ||
2020-06-09 | 2020-04-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2020-03-09 | 2020-01-31 | -0.13 | -0.13 | 0.0 | 0 | ||
2020-01-09 | 2019-10-31 | -0.24 | -0.1 | 0.14 | 58 | ||
2019-09-06 | 2019-07-31 | -0.23 | -0.11 | 0.12 | 52 | ||
2019-06-12 | 2019-04-30 | -0.23 | -0.13 | 0.1 | 43 | ||
2019-03-13 | 2019-01-31 | -0.15 | -0.23 | -0.08 | 53 | ||
2019-01-11 | 2018-10-31 | -0.15 | -0.26 | -0.11 | 73 | ||
2018-01-09 | 2017-10-31 | -0.12 | -0.12 | 0.0 | 0 |
Already Invested in Anixa Biosciences?
The danger of trading Anixa Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anixa Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anixa Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anixa Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.